Key insights
- Personalis SVP and Chief Legal Officer Stephen Moore sold $33,542 in shares to cover tax obligations. This occurs amidst a pending acquisition of Personalis by Tempus AI for approximately $1.5 billion, where Personalis shareholders will receive $16.25 per share in Tempus AI stock or cash. Needham downgraded Personalis to Hold from Buy following the acquisition announcement, while raising its price target to $17 due to takeover interest. Personalis also received UKCA marking for its NeXT Personal Dx test.
Stephen Michael Moore, Senior Vice President and Chief Legal Officer at Personalis, Inc. (NASDAQ:PSNL), disposed of shares totaling $33,542 on September 18, 2026.
The transaction involved the sale of 2,068 shares of Personalis common stock at a price of $16.22 per share. According to the filing, these shares were automatically sold to cover tax withholding obligations related to the settlement of vested restricted stock units. The sale comes as PSNL shares trade near $16.46, up 173% over the past year with a market cap of $1.76 billion, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. According to InvestingPro Tips, the stock has delivered strong returns but exhibits high volatility. Want deeper insights? PSNL is one of 1,400+ US equities covered by comprehensive Pro Research Reports.
Following this transaction, Mr. Moore directly holds 90,257 shares of Personalis common stock.
In other recent news, Tempus AI Inc. announced a definitive agreement to acquire Personalis Inc. in a transaction valued at approximately $1.5 billion, net of Tempus AI’s existing ownership interest. Personalis shareholders will receive $16.25 per share in Tempus AI stock, with the option for Tempus to fund up to 50% of the transaction in cash. This acquisition has led Needham to reiterate a Buy rating for Tempus AI, maintaining a price target of $75.00. Conversely, Needham downgraded Personalis to Hold from Buy following the acquisition announcement.
Additionally, Needham raised its price target for Personalis to $17 from $12, citing increased takeover interest from companies like Merck & Co. and others. In another development, Personalis received UKCA marking for its NeXT Personal Dx test, allowing its use in clinical settings across England, Wales, and Scotland. This regulatory clearance enhances the test’s applicability in multinational clinical trials. The acquisition by Tempus AI and regulatory advancements mark significant developments for both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI re-scores PSNL every month against thousands of alternatives on 100+ financial metrics, then builds the strategies that came out ahead.Energy Elite is beating its benchmark by 37% year to date. Mid Cap Movers by 21%. Tech Titans, our flagship, has beaten the S&P 500 by 112% since launch three years ago.See whether PSNL made the cut — and which stocks did.